MX2022005407A - Treating liver disorders. - Google Patents

Treating liver disorders.

Info

Publication number
MX2022005407A
MX2022005407A MX2022005407A MX2022005407A MX2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A MX 2022005407 A MX2022005407 A MX 2022005407A
Authority
MX
Mexico
Prior art keywords
treating liver
liver disorders
disorders
treating
manifestations
Prior art date
Application number
MX2022005407A
Other languages
Spanish (es)
Inventor
Kevin Klucher
Weidong Zhong
Martijn Fenaux
Yujin Wang
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of MX2022005407A publication Critical patent/MX2022005407A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided herein are methods and compositions for treating liver disorders, including without limitation non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient.
MX2022005407A 2019-11-08 2020-11-06 Treating liver disorders. MX2022005407A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933277P 2019-11-08 2019-11-08
US202063004403P 2020-04-02 2020-04-02
PCT/US2020/059522 WO2021092474A1 (en) 2019-11-08 2020-11-06 Treating liver disorders

Publications (1)

Publication Number Publication Date
MX2022005407A true MX2022005407A (en) 2022-05-24

Family

ID=75849579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005407A MX2022005407A (en) 2019-11-08 2020-11-06 Treating liver disorders.

Country Status (11)

Country Link
EP (1) EP4054567A4 (en)
JP (1) JP2023501386A (en)
KR (1) KR20220098168A (en)
CN (1) CN114667142A (en)
AU (1) AU2020380968A1 (en)
BR (1) BR112022008639A2 (en)
CA (1) CA3160445A1 (en)
CL (1) CL2022001167A1 (en)
IL (1) IL292459A (en)
MX (1) MX2022005407A (en)
WO (1) WO2021092474A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021400488A1 (en) 2020-12-14 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta e (inhbe) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20140187633A1 (en) * 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
KR20180124123A (en) * 2016-03-28 2018-11-20 인터셉트 파마슈티컬즈, 인크. Medicament obtained by combination of FXR agonist and ARB
US20200131129A1 (en) * 2017-03-15 2020-04-30 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2019023245A1 (en) * 2017-07-25 2019-01-31 Cedars-Sinai Medical Center Methods for treating liver diseases
JP2022508402A (en) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド Treatment of liver disorders

Also Published As

Publication number Publication date
CA3160445A1 (en) 2021-05-14
EP4054567A4 (en) 2024-01-10
CL2022001167A1 (en) 2023-02-10
AU2020380968A1 (en) 2022-05-12
WO2021092474A1 (en) 2021-05-14
EP4054567A1 (en) 2022-09-14
KR20220098168A (en) 2022-07-11
CN114667142A (en) 2022-06-24
IL292459A (en) 2022-06-01
BR112022008639A2 (en) 2022-07-19
JP2023501386A (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MX2021002305A (en) Treating liver disorders.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
WO2019099682A9 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
MX2017001656A (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof.
MX2009009761A (en) Compositions and kits for treating influenza.
MX2016010034A (en) Dihydropyrrolopyridine inhibitors of ror-gamma.
MX2010000465A (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders.
MX2015001122A (en) Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor.
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
EP2023926A4 (en) Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
BR112016018170A2 (en) Methods To Treat Alzheimer's Disease
MX350046B (en) Treatments for gastrointestinal disorders.
MX2016014731A (en) Treatment of the complications of chronic liver disease with caspase inhibitors.
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
MX2022014238A (en) Combination treatment of liver disorders.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
MX2021012634A (en) Neurogenesis.
TW200716561A (en) P38 inhibitors and methods of use thereof
IL288953A (en) Pharmaceutical compositions, kits and methods for treating tumors
MX2022005407A (en) Treating liver disorders.
MX2022005250A (en) Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies.
JOP20190164B1 (en) Compositions and methods for treating farber disease